nach oben

European Journal of Nutrition

Erschienen in:

12.06.2017 | Original Contribution

Amelioration of obesity-related characteristics by a probiotic formulation in a high-fat diet-induced obese rat model

verfasst von: Joo-Hyun Shin, Myung Hee Nam, Hyerim Lee, Joong-Su Lee, Hojun Kim, Myung-Jun Chung, Jae-Gu Seo

Erschienen in: European Journal of Nutrition | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Obesity is a major public health concern. Despite its multi-factorial etiology, alterations in intestinal microbiota and the immune system are frequently observed. We investigated the effect of Duolac Gold (DG), a probiotic formulation containing 2 Lactobacillus strains (L. acidophilus LA1 and L. rharmnosus LR5), 3 Bifidobacterium (B. bifidum BF3, B. lactis BL3, and B. longum BG7), and Streptococcus thermophilus ST3, on morphometric and metabolic parameters, intestinal microbiota, and intestinal immune responses in a high-fat diet (HFD)-induced obese rat model.

Methods

Rats received either a conventional balanced diet or HFD with or without water containing DG for 8 weeks. HFD-induced adiposity, intestinal microbiota, and changes in inflammatory cytokine, chemokine, and metabolite levels in serum were evaluated.

Results

DG administration effectively decreased HFD-induced body weight and modulated morphometric and metabolic parameters. Quantitative analysis of fecal microbiota showed that obese rats given DG exhibited significantly increased levels of Bacteroidetes, Lactobacillus, and Bifidobacterium, with significant decreases in the level of Firmicutes. Serum levels of the inflammatory cytokines and the chemokine were also altered. Serum metabolite analysis revealed that DG administration modulated HFD-induced changes in serum metabolites, including fatty acids (FA), lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine (PC), and triacylglycerol (TAG).

Conclusions

DG administration appears to have the potential to alleviate HDF-induced obesity through the modulation of intestinal microbiota, immune responses, and host metabolism, which supports the use of probiotics to treat obesity.

Nur mit Berechtigung zugänglich

Janghorbani M, Momeni F, Dehghani M (2012) Hip circumference, height and risk of type 2 diabetes: systematic review and meta-analysis. Obes Rev 13:1172–1181CrossRefPubMed

Jung DH, Kim JY, Kim JK, Koh SB, Park JK, Ahn SV (2014) Relative contribution of obesity and serum adiponectin to the development of hypertension. Diabetes Res Clin Pract 103:51–56CrossRefPubMed

Cani PD, Delzenne NM (2009) The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 15:1546–1558CrossRefPubMed

Moya-Perez A, Romo-Vaquero M, Tomas-Barberan F, Sanz Y, Garcia-Conesa MT (2014) Hepatic molecular responses to Bifidobacterium pseudocatenulatum CECT 7765 in a mouse model of diet-induced obesity. Nutr Metab Cardiovasc Dis 24:57–64CrossRefPubMed

Chen JJ, Wang R, Li XF, Wang RL (2011) Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression. Exp Biol Med (Maywood) 236:823–831CrossRef

Yoo SR, Kim YJ, Park DY, Jung UJ, Jeon SM, Ahn YT, Huh CS, McGregor R, Choi MS (2013) Probiotics L. plantarum and L. curvatus in combination alter hepatic lipid metabolism and suppress diet-induced obesity. Obesity 21:2571–2578CrossRefPubMed

Kang JH, Yun SI, Park HO (2010) Effects of Lactobacillus gasseri BNR17 on body weight and adipose tissue mass in diet-induced overweight rats. J Microbiol 48:712–714CrossRefPubMed

Yoon H, Yoon YS, Kim MS, Chung MJ, Yum DY (2014) A probiotic Preparation duolac-gold ameliorates dextran sulphate sodium-induced mouse colitis by downregulating the expression of IL-6. Toxicol Res 30:27–32CrossRefPubMedPubMedCentral

Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG (2014) Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastrol Hepatol 29:52–59CrossRef

10.

Kwak DS, Jun DW, Seo JG, Chung WS, Park SE, Lee KN, Khalid-Saeed W, Lee HL, Lee OY, Yoon BC, Choi HS (2014) Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. Eur J Gastrol Hepatol 26:1353–1359

11.

Yeun Y, Lee J (2015) Effect of a double-coated probiotic formulation on functional constipation in the elderly: a randomized, double blind, controlled study. Arch Pharm Res 38:1345–1350CrossRefPubMed

12.

Cani PD, Osto M, Geurts L, Everard A (2012) Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 3:279–288CrossRefPubMedPubMedCentral

13.

Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, Paek KS, Lee Y, Park JH (2006) Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta 1761:736–744CrossRefPubMed

14.

Takemura N, Okubo T, Sonoyama K (2010) Lactobacillus plantarum strain No. 14 reduces adipocyte size in mice fed high-fat diet. Exp Biol Med (Maywood) 235:849–856CrossRef

15.

Yin YN, Yu QF, Fu N, Liu XW, Lu FG (2010) Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World J Gastroenterol 16:3394–3401CrossRefPubMedPubMedCentral

16.

Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A, Chakraborty C, Singh B, Marotta F, Jain S, Yadav H (2012) Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012:902917CrossRefPubMedPubMedCentral

17.

Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran LG, Smirnova N, Berge M, Sulpice T, Lahtinen S, Ouwehand A, Langella P, Rautonen N, Sansonetti PJ, Burcelin R (2011) Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 3:559–572CrossRefPubMedPubMedCentral

18.

Stenman LK, Burcelin R, Lahtinen S (2015) Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans—towards treatment with probiotics. Benef Microbes 7:1–12

19.

Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023CrossRefPubMed

20.

Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI (2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102:11070–11075CrossRefPubMedPubMedCentral

21.

Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334:105–108CrossRefPubMedPubMedCentral

22.

Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:1470–1481CrossRefPubMed

23.

Jung UJ, Choi MS (2014) Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 15:6184–6223CrossRefPubMedPubMedCentral

24.

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmee E, Cousin B, Sulpice T, Chamontin B, Ferrieres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761–1772CrossRefPubMed

25.

Yi LZ, He J, Liang YZ, Yuan DL, Chau FT (2006) Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS-LDA. FEBS Lett 580:6837–6845CrossRefPubMed

26.

Eisinger K, Liebisch G, Schmitz G, Aslanidis C, Krautbauer S, Buechler C (2014) Lipidomic analysis of serum from high fat diet induced obese mice. Int J Mol Sci 15:2991–3002CrossRefPubMedPubMedCentral

27.

Abbott MJ, Tang T, Sul HS (2010) The role of phospholipase A(2)-derived mediators in obesity. Drug Discov Today Dis Mech 7:e213–e218CrossRefPubMedPubMedCentral

28.

Yaligar J, Gopalan V, Kiat OW, Sugii S, Shui G, Lam BD, Henry CJ, Wenk MR, Tai ES, Velan SS (2014) Evaluation of dietary effects on hepatic lipids in high fat and placebo diet fed rats by in vivo MRS and LC-MS techniques. PLoS ONE 9:e91436CrossRefPubMedPubMedCentral

29.

Kim HJ, Kim JH, Noh S, Hur HJ, Sung MJ, Hwang JT, Park JH, Yang HJ, Kim MS, Kwon DY, Yoon SH (2011) Metabolomic analysis of livers and serum from high-fat diet induced obese mice. J Proteome Res 10:722–731CrossRefPubMed

30.

Kim HY, Kim M, Park HM, Kim J, Kim EJ, Lee CH, Park JH (2014) Lysophospholipid profile in serum and liver by high-fat diet and tumor induction in obesity-resistant BALB/c mice. Nutrition 30:1433–1441CrossRefPubMed

31.

Kim JY, Park JY, Kim OY, Ham BM, Kim HJ, Kwon DY, Jang Y, Lee JH (2010) Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). J Proteome Res 9:4368–4375CrossRefPubMed

32.

Vargas-Robles H, Rios A, Arellano-Mendoza M, Escalante BA, Schnoor M (2015) Antioxidative diet supplementation reverses high-fat diet-induced increases of cardiovascular risk factors in mice. Oxid Med Cell Logev 2015:467471

33.

Vecka M, Richterova B, Zak A, Tvrzicka E, Sramkova P, Stankova B, Klimcakova E, Stich V (2006) Changes in serum and adipose tissue fatty acid composition after low calorie diet with respect to dietary fat content in obese. Cas Lek Cesk 145:464–469PubMed

34.

Kotronen A, Velagapudi VR, Yetukuri L, Westerbacka J, Bergholm R, Ekroos K, Makkonen J, Taskinen MR, Oresic M, Yki-Jarvinen H (2009) Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 52:684–690CrossRefPubMed

35.

Lee SJ, Bose S, Seo JG, Chung WS, Lim CY, Kim H (2014) The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: a randomized double-blind controlled clinical trial. Clin Nutr 33:973–981CrossRefPubMed

Titel: Amelioration of obesity-related characteristics by a probiotic formulation in a high-fat diet-induced obese rat model
verfasst von: Joo-Hyun Shin
Myung Hee Nam
Hyerim Lee
Joong-Su Lee
Hojun Kim
Myung-Jun Chung
Jae-Gu Seo
Publikationsdatum: 12.06.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 6/2018
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-017-1481-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Amelioration of obesity-related characteristics by a probiotic formulation in a high-fat diet-induced obese rat model